A comparative study of two hormone replacement therapy regimens on safety and efficacy variables

Siseles, Néstor; Halperin, H; Benencia, H; Berg, Gabriela; Susana, Pilnik; Mesch, Viviana; Arrighi, Beatriz; Wikinski, Regina

doi:10.1016/0378-5122(94)00889-f

Cited by 38 publications

(14 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In agreement with previous studies, we demonstrate that both CEE/MPA and tibolone reduce total cholesterol significantly 15, [26][27][28] . Also triglyceride-rich lipoproteins may play potential roles in cardiovascular diseases as well as the metabolic syndrome 29,30 .…”

Section: Discussionsupporting

confidence: 94%

The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors

et al. 2008

View full text Add to dashboard Cite

show abstract

Section: Discussionsupporting

confidence: 94%

The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Findings from the present study regarding the relief of vasomotor and central nervous system-related symptoms are consistent with the well-documented literature for oral combined HT [22][23][24][25].…”

Section: Discussionsupporting

confidence: 93%

“…The present bleeding results are also consistent with the published literature regarding the incidence, characteristics and duration of breakthrough bleeding episodes among women taking oral HT regimens [ [22][23][24]32]. Likewise, bleeding episodes were generally characterised as spotting or mild bleeding with a duration most commonly of 1-3 days.…”

Section: Discussionsupporting

confidence: 92%

An open-label study of subdermal implants of estradiol-onlyversussubdermal implants of estradiol plus nomegestrol acetate: effects on symptom control, lipid profile and tolerability

Barbosa¹,

Oladapo²,

Noronha³

et al. 2009

Gynecological Endocrinology

View full text Add to dashboard Cite

show abstract

“…In addition, any effects of tibolone on the endometrium and breast are minimal [26,27]. In the endometrium, tibolone is extensively metabolized to its D 4 -isomer, which has progestogenic and androgenic activities.Thus, concomitant administration of progestogens with tibolone treatment is not required, and high levels of amenorrhea are achieved [25].…”

Section: Introductionmentioning

confidence: 99%

Randomized, Double-masked, 2-year Comparison of Tibolone with 17β-Estradiol and Norethindrone Acetate in Preventing Postmenopausal Bone Loss

et al. 2002

View full text Add to dashboard Cite

In this 2-year, randomized study, we compared the efficacy and tolerability of tibolone 2.5 mg (n = 75), tibolone 1.25 mg (n = 76) and estradiol 2 mg plus norethindrone acetate 1 mg (E2/NETA: n = 74) for preventing bone loss in postmenopausal women. Bone mineral density (BMD), measured by dual-energy X-ray absorptiometry, and bone remodeling markers were assessed every 6 months. Side-effects were assessed quarterly. After 24 months, the mean increase (+/- SD) in lumbar spine BMD from baseline was 3.6% +/- 2.9%, 1.9% +/- 3.5% and 6.8% +/- 4.5% in the tibolone 2.5 mg, tibolone 1.25 mg and E2/NETA groups, respectively. All pairwise differences were significant. The proportion of responders (women with a change from baseline in lumbar spine BMD of > or = -2% after 2 years) was 95.7%, 89.0% and 98.5% with tibolone 2.5 mg, tibolone 1.25 mg and E2/NETA, respectively. Similar results were obtained for femoral BMD, although the difference between tibolone 2.5 mg and E2/NETA was not significant at 24 months. Decreases in bone remodeling markers were similar in the three groups. Vaginal bleeding was more common in the E2/ NETA group (33.8%) than with tibolone 2.5 mg (12.0%) or tibolone 1.25 mg (9.2%), as was breast pain (23.0%, 2.7% and 2.6%, respectively). Each treatment effectively prevented bone loss. Overall, tolerability of tibolone was better than with E2/NETA, because of less frequent vaginal bleeding and breast pain. This may promote long-term adherence.

show abstract

A comparative study of two hormone replacement therapy regimens on safety and efficacy variables

Cited by 38 publications

References 47 publications

The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors

The effect of continuous combined conjugated equine estrogen plus medroxyprogesterone acetate and tibolone on cardiovascular metabolic risk factors

An open-label study of subdermal implants of estradiol-onlyversussubdermal implants of estradiol plus nomegestrol acetate: effects on symptom control, lipid profile and tolerability

Randomized, Double-masked, 2-year Comparison of Tibolone with 17β-Estradiol and Norethindrone Acetate in Preventing Postmenopausal Bone Loss

Contact Info

Product

Resources

About